Payment overview · 2025
General Payments
$602.06
32 reported records · 11 companies
Healthcare provider profile · identity verified
Fredrick S Dibrell, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PIKEVILLE, TN · NPI 1285654111
Verified facts
What the public records show
CMS Open Payments records show Fredrick S Dibrell, M.D. received $602.06 in general payments during 2025 across 32 reported records.
Novo Nordisk Inc accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 339 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 334 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 339 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $189.56 | 31.5% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.83 | 16.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.52 | 12.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.62 | 12.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $48.54 | 8.1% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.22 | 3.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.97 | 3.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.03 | 3.3% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.45 | 3.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.39 | 3.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.93 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $602.06 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $160.93 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $160.93 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.62 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.62 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $59.49 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48.54 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.63 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 20 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 236 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 334 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
236 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
339 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
334 | 57 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
339 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 872 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 802 | 124 |
| Potassium Chloride | Potassium Chloride | 788 | 117 |
| Furosemide | Furosemide | 611 | 88 |
| Losartan Potassium | Losartan Potassium | 542 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 487 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 470 | 113 |
| Metoprolol Tartrate | Metoprolol Tartrate | 454 | 67 |
| Gabapentin | Gabapentin | 424 | 74 |
| Omeprazole | Omeprazole | 419 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 417 | 112 |
| Metformin Hcl | Metformin Hcl | 392 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 373 | 76 |
| Eliquis | Apixaban | 339 | 45 |
| Ozempic | Semaglutide | 334 | 57 |
| Carvedilol | Carvedilol | 302 | 81 |
| Lisinopril | Lisinopril | 302 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 263 | 65 |
| Trazodone Hcl | Trazodone Hcl | 258 | 47 |
| Divalproex Sodium | Divalproex Sodium | 249 | 17 |
| Farxiga | Dapagliflozin Propanediol | 236 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 230 | 79 |
| Sertraline Hcl | Sertraline Hcl | 223 | 40 |
| Alprazolam | Alprazolam | 209 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 169 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 38 |
| Pregabalin | Pregabalin | 160 | 21 |
| Promethazine Hcl | Promethazine Hcl | 157 | 17 |
| Lorazepam | Lorazepam | 154 | 30 |
| Tramadol Hcl | Tramadol Hcl | 149 | 23 |
| Xarelto | Rivaroxaban | 148 | 24 |
| Sucralfate | Sucralfate | 143 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 44 |
| Mirtazapine | Mirtazapine | 141 | 25 |
| Buspirone Hcl | Buspirone Hcl | 139 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 33 |
| Famotidine | Famotidine | 132 | 30 |
| Glimepiride | Glimepiride | 132 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 129 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 120 | 22 |
| Donepezil Hcl | Donepezil Hcl | 119 | 16 |
| Nystatin | Nystatin | 118 | 47 |
| Doxycycline Hyclate | Doxycycline Hyclate | 114 | 89 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 17 |
| Montelukast Sodium | Montelukast Sodium | 107 | 27 |
| Amoxicillin | Amoxicillin | 106 | 65 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 24 |
| Clonazepam | Clonazepam | 98 | 18 |
| Metformin Hcl Er | Metformin Hcl | 97 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 23 |
| Ezetimibe | Ezetimibe | 91 | 26 |
| Gemtesa | Vibegron | 89 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 86 | 19 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 85 | suppressed |
| Azithromycin | Azithromycin | 83 | 66 |
| Carbamazepine | Carbamazepine | 82 | suppressed |
| Jardiance | Empagliflozin | 82 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 81 | 11 |
| Bumetanide | Bumetanide | 81 | 22 |
| Entresto | Sacubitril/Valsartan | 81 | suppressed |
| Atenolol | Atenolol | 80 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 79 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 21 |
| Diazepam | Diazepam | 78 | 14 |
| Simvastatin | Simvastatin | 76 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 35 |
| Glipizide | Glipizide | 75 | 21 |
| Mupirocin | Mupirocin | 75 | 54 |
| Memantine Hcl | Memantine Hcl | 74 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 73 | 14 |
| Levetiracetam | Levetiracetam | 70 | suppressed |
| Trulicity | Dulaglutide | 70 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 18 |
| Olanzapine | Olanzapine | 69 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 69 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 15 |
| Methocarbamol | Methocarbamol | 65 | 20 |
| Spironolactone | Spironolactone | 65 | 18 |
| Ramipril | Ramipril | 64 | 13 |
| Baclofen | Baclofen | 63 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 63 | suppressed |
| Valsartan | Valsartan | 62 | 19 |
| Cephalexin | Cephalexin | 60 | 42 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | 12 |
| Benazepril Hcl | Benazepril Hcl | 55 | 14 |
| Bupropion Xl | Bupropion Hcl | 55 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 55 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 54 | 14 |
| Prednisone | Prednisone | 53 | 21 |
| Bydureon Bcise | Exenatide Microspheres | 52 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 50 | 42 |
| Warfarin Sodium | Warfarin Sodium | 50 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 16 |
| Synthroid | Levothyroxine Sodium | 48 | 13 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Allopurinol | Allopurinol | 46 | 12 |
| Celecoxib | Celecoxib | 43 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Fluconazole | Fluconazole | 41 | 21 |
| Lithium Carbonate | Lithium Carbonate | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | suppressed |
| Finasteride | Finasteride | 39 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 14 |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 30 |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 14 |
| Estradiol | Estradiol | 32 | 11 |
| Ibuprofen | Ibuprofen | 32 | 18 |
| Methylprednisolone | Methylprednisolone | 32 | 30 |
| Phenytoin | Phenytoin | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | 11 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 30 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 30 | 26 |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Lacosamide | Lacosamide | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 27 | 27 |
| Temazepam | Temazepam | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Meloxicam | Meloxicam | 26 | 13 |
| Digoxin | Digoxin | 25 | suppressed |
| Haloperidol | Haloperidol | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Indapamide | Indapamide | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Galantamine Er | Galantamine Hbr | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 20 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Insulin Lispro | Insulin Lispro | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Loxapine | Loxapine Succinate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Tirosint-Sol | Levothyroxine Sodium | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $602.06 · 32 records | Novo Nordisk Inc | ABRYSVO, BRILINTA, CAMZYOS, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, GVOKE HYPOPEN, Jornay PM, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR, VYNDAMAX, VYNDAQEL, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error